Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab + Regorafenib in solid tumors
NCT04200404Phase 2Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- May 2021
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of sugemalimab in solid tumor, gastric cancer (GC), sponsored by CStone Pharmaceuticals. Started Dec 2019; status: completed.
02
Drugs
sugemalimab
03
Conditions
solid tumorgastric cancer (GC)
Beyond the preview
Go deeper on NCT04200404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04200404.